Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin in Subjects With Type 2 Diabetes (SUSTAIN - CHINA MRCT)
- Disease/Condition
- Diabetes,Diabetes Mellitus, Type 2
- Drug/Device/Intervention
- Semaglutide 0.5 mg
- Study type
- Interventional
- Intervention type
- drug
- Primary sponsor
- Novo Nordisk A/S
- Location
- Aparecida de Goiania,Porto Alegre,São Paulo,Hefei,Hefei,Beijing,Beijing,Beijing,Beijing,Beijing,ChongQing,Fuzhou,Guangzhou,Guangzhou,Guangzhou,Zhuhai,Guiyang,Qiqihar,Chenzhou,Changzhou,Nanjing,Nanjing, Brazil,China,China,South Korea,South Africa,Taiwan,Ukraine
- Phase
- Phase 3
- Start date
- Aug 28, 2017
- End date
- Apr 15, 2019
- Enrollment
- 868 participants
Change in HbA1c
This trial is conducted in Africa, Asia, Europe and South America. The aim of the trial is to
 compare the effect of once-weekly dosing of two dose levels of semaglutide versus sitagliptin
 100 mg once-daily on glycaemic control after 30 weeks of treatment. Subjects will remain on
 their stable pre-trial metformin.
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT03061214
- Type
- Non-Device Trial
Access comprehensive clinical trial information for NCT03061214 through Pure Global AI's free database. This Phase 3 trial is sponsored by Novo Nordisk A/S and is currently Completed. The study focuses on Diabetes,Diabetes Mellitus, Type 2. Target enrollment is 868 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.